(Q28277125)

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study (English)

0 references

main subject

inflammation

0 references

lip and oral cavity carcinoma

1 reference

J Sudbø

1

0 references

J J Lee

2

0 references

S M Lippman

3

0 references

J Mork

4

0 references

S Sagen

5

0 references

N Flatner

6

0 references

A Ristimäki

7

0 references

A Sudbø

8

0 references

L Mao

9

0 references

X Zhou

10

0 references

W Kildal

11

0 references

J F Evensen

12

0 references

A Reith

13

0 references

A J Dannenberg

Retraction--Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study

14

0 references

language of work or name

English

0 references

publication date

October 2005

1 reference

0 references

366

0 references

issue

9494

0 references

page(s)

1359-66

0 references

is retracted by

0 references

cites work

Cancer mortality trends in the EU and acceding countries up to 2015.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

DNA content as a prognostic marker in patients with oral leukoplakia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Focus on head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

The influence of resection and aneuploidy on mortality in oral leukoplakia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

The ethics of policies for the prevention of tobacco disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Improving physician-delivered counseling in a primary care setting: lessons from a failed attempt

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

A meta-evaluation of 11 school-based smoking prevention programs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

The white lesion that kills--aneuploid dysplastic oral leukoplakia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Prostaglandins in carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Prostaglandin H synthase and xenobiotic oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Carcinogen substrate specificity of human COX-1 and COX-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Oral mucosal tumor inhibition by ibuprofen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Aspirin use and cancers of the upper aerodigestive tract

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

National databases and rheumatology research I: longitudinal databases in Scandinavia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Extensions of analytic methods for nested and population-based incident case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Epidemiology of non-steroidal anti-inflammatory drugs and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cyclooxygenase-2 and gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Prostaglandin synthetase dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo(a)pyrene to mutagenic derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Too many rodent carcinogens: mitogenesis increases mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cell proliferation in carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

The impact of smoking habits on lung cancer risk: 28 years' observation of 26,000 Norwegian men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021

The convergence of cancer prevention and therapy in early-phase clinical drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967488-0

7 January 2021